Search results
Professor Andrew Cope . Professor of Rheumatology. Head of the Centre for Rheumatic Diseases
Feb 14, 2024 · Professor Andrew Cope, Professor of Rheumatology from School of Immunology & Microbial Sciences Secondary outcomes for the trial showed that abatacept was associated with improvements in pain scores, function and quality of life measurements, as well as lower scores of inflammation of the lining of joints detectable by ultrasound scan.
- 5-11 Lavington Street, London, SE1 0NZ
- comms@kcl.ac.uk
- 020 7848 3202
Andrew COPE, Arthritis Research UK Professor of Rheumatology | Cited by 10,205 | of King's College London, London (KCL) | Read 345 publications | Contact Andrew COPE.
301. 2010. Chronic exposure to tumor necrosis factor (TNF) in vitro impairs the activation of T cells through the T cell receptor/CD3 complex; reversal in vivo by anti-TNF antibodies in …. AP Cope, M Londei, NR Chu, SB Cohen, MJ Elliott, FM Brennan, ... The Journal of clinical investigation 94 (2), 749-760.
Feb 14, 2024 · Professor Andrew Cope, of King’s College London, said: “This is the largest rheumatoid arthritis prevention trial to date and the first to show that a therapy licensed for use in treating...
Feb 13, 2024 · Professor Andrew Cope, from King's College London, said, "This is the largest rheumatoid arthritis prevention trial to date and the first to show that a therapy licensed for use in treating...
Find a list of Andrew Cope's publications on KCL PURE . Phone: 020 7484 6901. Email: andrew.cope@kcl.ac.uk. Inflammatory arthritis including rheumatoid arthritis. Prevention studies in subjects at high risk of rheumatoid arthritis. Immune mediated inflammatory diseases. Rheumatic syndromes in cancer patients. Clinical trials.
